- Home
- VMRK vs EW Comparison
VMRK vs EW Comparison
Compare VMRK & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VMRK | EW |
|---|---|---|
| Founded | N/A | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Industrial Specialties |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.8B | 48.9B |
| IPO Year | 1994 | 1999 |
Fundamental Metrics
Financial Performance| Metric | VMRK | EW |
|---|---|---|
| Price | $61.45 | $88.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 21 |
| Target Price | N/A | ★ $96.37 |
| AVG Volume (30 Days) | ★ 5.4M | 2.7M |
| Earning Date | N/A | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.09 | N/A |
| EPS | 0.54 | ★ 1.07 |
| Revenue | $2,701,075,000.00 | ★ $6,067,600,000.00 |
| Revenue This Year | N/A | $13.39 |
| Revenue Next Year | N/A | $9.81 |
| P/E Ratio | $113.35 | ★ $82.50 |
| Revenue Growth | 4.76 | ★ 11.55 |
| 52 Week Low | $61.17 | $72.30 |
| 52 Week High | $66.45 | $96.29 |
Technical Indicators
Market Signals| Indicator | VMRK | EW |
|---|---|---|
| Relative Strength Index (RSI) | 32.62 | 49.46 |
| Support Level | N/A | $81.96 |
| Resistance Level | $66.40 | $89.28 |
| Average True Range (ATR) | 1.21 | 2.13 |
| MACD | -0.45 | 0.00 |
| Stochastic Oscillator | 14.09 | 50.11 |
Price Performance
Historical ComparisonAbout VMRK Vivmark Residential Common Shares of Beneficial Interest
Vivmark owns a high-quality apartment portfolio with around 184,000 units and is developing another $4.4 billion of residential properties. The company focuses on owning large, high-quality properties in major metropolitan areas of New England, New York/New Jersey, Washington, D.C., California, and the Pacific Northwest.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.